Clinical Trial Imaging Market by Software & Service (Operational Imaging, Trial Design), Modality (CT, MRI, X-Ray, PET, Ultrasound), Therapeutic Area (Infectious, Oncology, CNS, CVD), End User (Pharma, Biotech, CROs) - Global Forecast to 2029
세계의 임상시험 이미징 시장 규모는 2024년 14억 2,000만 달러에서 2029년까지 20억 7,000만 달러에 달할 것으로 예측되며, CAGR로 7.8%의 성장이 전망됩니다.
시장의 성장 촉진요인은 바이오테크놀러지 및 제약 산업의 확대, 연구개발비용 증가, CRO(임상시험 수탁기관)의 수 등이 있습니다. 반면, 예측 기간 중 시장 성장을 저해하는 주요 요인은 높은 임상시험 비용과 높은 영상 시스템 도입 비용입니다.
| 조사 범위 |
| 조사 대상년 |
2022-2029년 |
| 기준년 |
2023년 |
| 예측 기간 |
2024-2029년 |
| 단위 |
10억 달러 |
| 부문 |
서비스·소프트웨어별, 모달리티별, 치료 영역별, 최종사용자별, 지역별 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카, GCC |
"서비스·소프트웨어별에서는 서비스 부문이 예측 기간 중 시장에서 가장 빠른 성장률을 기록했습니다."
2023년 임상시험 이미징 시장에서 서비스 부문이 가장 빠른 성장률을 보였습니다. R&D 비용 증가, 임상시험 증가, 새로운 질병 치료 및 진단에 대한 요구가 이 부문의 성장에 기여하는 주요 요인으로 꼽힙니다.
"의료기기 제조업체 부문이 가장 높은 CAGR을 기록했습니다."
2023년 가장 높은 성장률을 기록한 부문은 의료기기 제조업체였습니다. 이는 의료기기 제조업체 부문의 주요 성장 요인이 의료기기 제조업체의 R&D 비용 증가와 R&D 활동, 의료기기 시장의 성장으로 설명할 수 있습니다.
"아시아태평양: 가장 빠르게 성장하는 임상시험 이미징 시장"
아시아태평양은 예측 기간 중 가장 높은 CAGR을 나타낼 것으로 예상됩니다. 다수의 중소기업, 임상시험을 위한 대규모 미치료 인구, 임상 연구에서 동물 사용에 대한 덜 엄격한 규제, 규제와 언어에 대한 이해도가 높은 현지 CRO의 가용성, 고도로 숙련된 연구자의 존재, 낮은 임상시험 비용 등이 R&D 부문의 주요 촉진요인으로 작용하고 있습니다. 입니다. 이러한 촉진요인은 R&D 비용 증가와 아시아 개발도상국으로의 의약품 연구 아웃소싱 증가 추세에 기인합니다.
세계의 임상시험 이미징 시장에 대해 조사분석했으며, 주요 촉진요인과 억제요인, 경쟁 구도, 향후 동향 등의 정보를 제공하고 있습니다.
목차
제1장 서론
제2장 조사 방법
제3장 개요
제4장 주요 인사이트
- 임상시험 이미징 시장의 개요
- 임상시험 이미징 시장 점유율 : 서비스·소프트웨어별(2024년·2029년)
- 임상시험 이미징 시장 점유율 : 모달리티별(2024년·2029년)
- 임상시험 이미징 시장 점유율 : 치료 영역별(2024년·2029년)
- 임상시험 이미징 시장 점유율 : 최종사용자별(2024년·2029년)
- 임상시험 이미징 시장 : 지역의 성장 기회
제5장 시장의 개요
- 서론
- 시장 역학
- 가격 분석
- 특허 분석
- 무역 분석
- X선 장비의 무역 분석(HS 코드 9022)
- CT 장비의 무역 분석(HS 코드 902212)
- 밸류체인 분석
- 공급망 분석
- 에코시스템 분석
- Porter's Five Forces 분석
- 주요 이해관계자와 구입 기준
- 규제 분석
- 주요 컨퍼런스와 이벤트(2023-2024년)
- 기술 분석
- 고객 비즈니스에 영향을 미치는 동향/혼란
- 사례 연구 분석
- 임상시험 이미징 시장에 대한 AI/생성형 AI의 영향
제6장 임상시험 이미징 시장 : 서비스·소프트웨어별
- 서론
- 서비스
- 운영 이미징 서비스
- 리드 애널리시스 서비스
- 시스템, 기술 지원 서비스
- 시험 설계, 컨설팅 서비스
- 소프트웨어
제7장 임상시험 이미징 시장 : 모달리티별
- 서론
- CT
- MRI
- 초음파
- PET
- X선
- 기타 모달리티
제8장 임상시험 이미징 시장 : 치료 영역별
- 서론
- 종양
- 감염증
- 신경
- 심혈관 장애
- 내분비
- 면역 질환
- 기타 치료 영역
제9장 임상시험 이미징 시장 : 최종사용자별
- 서론
- 제약·바이오테크놀러지 기업
- 의료기기 제조업체
- CRO
- 학술기관, 정부 연구기관
- 기타 최종사용자
제10장 임상시험 이미징 시장 : 지역별
- 서론
- 북미
- 유럽
- 유럽의 거시경제 전망
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
- 아시아태평양
- 아시아태평양의 거시경제 전망
- 중국
- 일본
- 인도
- 기타 아시아태평양
- 라틴아메리카
- 라틴아메리카의 거시경제 전망
- 브라질
- 멕시코
- 기타 라틴아메리카
- 중동 및 아프리카
- GCC 국가
제11장 경쟁 구도
- 서론
- 주요 기업 전략/유력 기업
- 매출 분석(2021-2023년)
- 시장 점유율 분석(2023년)
- 기업의 평가 매트릭스 : 주요 기업(2023년)
- 기업의 평가 매트릭스 : 스타트업/중소기업(2023년)
- 기업의 평가와 재무 지표
- 경쟁 시나리오
제12장 기업 개요
- 주요 기업
- ICON PLC
- MEDPACE
- CLARIO
- IXICO PLC
- RESONANCE HEALTH LTD.
- RADIANT SAGE
- WCG CLINICAL
- CARDIOVASCULAR IMAGING TECHNOLOGIES
- 기타 기업
- MEDICAL METRICS, INC.
- PRISM CLINICAL IMAGING
- BOSTON IMAGING CORE LAB
- VOIANT
- CALYX
- BIOSPECTIVE INC.
- PROSCAN IMAGING
- MICRON, INC.
- IMAGING ENDPOINTS
- PERSPECTUM
- PHARMTRACE
- NAVITAS LIFE SCIENCES
- MEDIAN TECHNOLOGIES
- INVICRO, LLC
- IMAGE CORE LAB
- IMAGE ANALYSIS GROUP(IAG)
제13장 부록
KSA
According to projections, the global clinical trial imaging market is expected to grow at a compound annual growth rate (CAGR) of 7.8%, from USD 1.42 billion in 2024 to USD 2.07 billion by 2029. Factors driving the market's growth include the biotechnology and pharmaceutical industries' expansion, the rise in R&D spending, and the number of Contract Research Organizations (CROs). However, the primary factors impeding the market's growth during the projection period are the high cost of clinical trials and the high implementation cost of imaging systems.
| Scope of the Report |
|---|
| Years Considered for the Study | 2022-2029 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Units Considered | Value (USD Billion) |
| Segments | By Service & software, modality, therapeutic area, end user and region |
| Regions covered | North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC |
"By service & software, the service sector had the fastest growth rate in the clinical trial imaging market throughout the projected period."
Based on type, services and software comprise the clinical trial imaging industry. In the clinical trial imaging market in 2023, the service sector had the fastest growth rate. The operational imaging services, reader analysis services, system & technical support services, and trial design consulting services are further subdivided under the services sector based on type. Growing R&D expenditures, an increase in clinical trials, and the need for novel illness treatments and diagnostics are the main factors contributing to this segment's growth.
"Medical device manufacturers segment accounted for the highest CAGR."
The pharmaceutical and biotechnology firms, medical device manufacturers, contract research organizations, academic and government research institutes, and other end users are the segments of the clinical trial imaging market based on end user. The segment with the highest growth rate in 2023 was medical device manufacturers. This can be explained by the fact that the major growth drivers of the medical device manufacturers segment are the rising R&D expenditures and R&D activity by medical device manufacturers as well as the growing medical device market.
"Asia Pacific: The fastest-growing region clinical trial imaging market."
The markets for clinical trial imaging across North America, Europe, Asia Pacific, Latin America, the Middle East and Africa and GCC countries comprise the global market. Over the course of the projection period, the Asia Pacific area is expected to record the greatest CAGR. The large number of SMEs, the presence of a large treatment-naive population for clinical trials, less-stringent regulations governing the use of animals in clinical research, the availability of local CROs with strong regulatory and linguistic understanding, the presence of highly qualified researchers, and the low cost of clinical trials are the major factors driving the R&D sector. These drivers driving the market's expansion are therefore due to the rise in R&D expenditures and the increasing trend of outsourcing pharmaceutical research to developing Asian countries.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
- By Designation: C-level - 27%, D-level - 18%, and Others - 55%
- By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and the Middle East & Africa - 4%
Prominent companies are ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), BioClinica Inc. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US), Medical Metrics Inc. (US), Prism Clinical Imaging, Inc. (US), Boston Imaging Core Lab LLC. (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC. (US), Micron Inc. (Japan), Imaging Endpoints LI, LLC (US), Perspectum Ltd. (UK), Pharmtrace klinische Entwicklung GmbH (Germany), WorldCare Clinical, LLC (US), Median Technologies (France) and Invicro. LLC. (US).
Research Coverage:
This research report categorizes the clinical trial imaging market by service & software, modality, therapeutic area, end user and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the clinical trial imaging market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the clinical trial imaging market. Competitive analysis of upcoming startups in the clinical trial imaging market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial imaging market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the clinical trial imaging market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the clinical trial imaging market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the clinical trial imaging market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the clinical trial imaging market.
- Competitive Assessment: In-depth assessment of market ranking, growth strategies and service offerings of leading players like ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), and Medpace Holdings, Inc. (US), among others in the clinical clinical trial imaging market strategies.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 SEGMENTS CONSIDERED
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.2 RESEARCH APPROACH
- 2.2.1 SECONDARY DATA
- 2.2.1.1 Key data from secondary sources
- 2.2.1.2 Objectives of secondary research
- 2.2.2 PRIMARY DATA
- 2.2.2.1 Objectives of primary research
- 2.2.2.2 Key data from primary sources
- 2.2.2.3 Key industry insights
- 2.2.2.4 Breakdown of primaries
- 2.3 MARKET SIZE ESTIMATION
- 2.3.1 BOTTOM-UP APPROACH
- 2.3.1.1 Company revenue estimation approach
- 2.3.1.2 Company presentations and primary interviews
- 2.3.1.3 Growth forecasts
- 2.3.1.4 CAGR projections
- 2.3.2 TOP-DOWN APPROACH
- 2.4 DATA TRIANGULATION
- 2.5 STUDY ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 CLINICAL TRIAL IMAGING MARKET OVERVIEW
- 4.2 CLINICAL TRIAL IMAGING MARKET SHARE, BY SERVICE & SOFTWARE, 2024 VS. 2029
- 4.3 CLINICAL TRIAL IMAGING MARKET SHARE, BY MODALITY, 2024 VS. 2029
- 4.4 CLINICAL TRIAL IMAGING MARKET SHARE, BY THERAPEUTIC AREA, 2024 VS. 2029
- 4.5 CLINICAL TRIAL IMAGING MARKET SHARE, BY END USER, 2024 VS. 2029
- 4.6 CLINICAL TRIAL IMAGING MARKET: REGIONAL GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Increasing R&D spending in pharmaceutical and biotechnology companies
- 5.2.1.2 Rising number of clinical trials in medical research
- 5.2.1.3 Growth in pharmaceutical and biotechnology industries
- 5.2.1.4 Increasing number of contract research organizations
- 5.2.2 RESTRAINTS
- 5.2.2.1 High implementation cost of imaging systems
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Growth opportunities in emerging economies
- 5.2.3.2 Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals
- 5.2.4 CHALLENGES
- 5.2.4.1 High cost of clinical trials
- 5.3 PRICING ANALYSIS
- 5.3.1 INDICATIVE PRICING ANALYSIS FOR CLINICAL TRIAL IMAGING SERVICES & SOFTWARE, 2021-2023
- 5.4 PATENT ANALYSIS
- 5.4.1 LIST OF MAJOR PATENTS, 2022-2023
- 5.5 TRADE ANALYSIS
- 5.5.1 TRADE ANALYSIS FOR X-RAY APPARATUS (HS CODE 9022)
- 5.5.1.1 Import data for X-ray apparatus
- 5.5.1.2 Export data for X-ray apparatus
- 5.5.2 TRADE ANALYSIS FOR CT APPARATUS (HS CODE 902212)
- 5.5.2.1 Import data for CT apparatus
- 5.5.2.2 Export data for CT apparatus
- 5.6 VALUE CHAIN ANALYSIS
- 5.7 SUPPLY CHAIN ANALYSIS
- 5.8 ECOSYSTEM ANALYSIS
- 5.9 PORTER'S FIVE FORCES ANALYSIS
- 5.9.1 THREAT OF NEW ENTRANTS
- 5.9.2 THREAT OF SUBSTITUTES
- 5.9.3 BARGAINING POWER OF BUYERS
- 5.9.4 BARGAINING POWER OF SUPPLIERS
- 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.10.2 KEY BUYING CRITERIA
- 5.11 REGULATORY ANALYSIS
- 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.12 KEY CONFERENCES AND EVENTS IN 2023-2024
- 5.13 TECHNOLOGY ANALYSIS
- 5.13.1 KEY TECHNOLOGIES
- 5.13.2 COMPLEMENTARY TECHNOLOGIES
- 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.15 CASE STUDY ANALYSIS
- 5.15.1 REVIEW OF CT FINDINGS AND HISTOPATHOLOGICAL CHARACTERISTICS OF PRIMARY LIVER CARCINOSARCOMA
- 5.16 IMPACT OF AI/GENERATIVE AI ON CLINICAL TRIAL IMAGING MARKET
6 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE
- 6.1 INTRODUCTION
- 6.2 SERVICES
- 6.2.1 OPERATIONAL IMAGING SERVICES
- 6.2.1.1 Rising number of CROs and growing pharmaceutical industry to drive market
- 6.2.2 READ ANALYSIS SERVICES
- 6.2.2.1 Increasing number of clinical trials and rising R&D spending to support market growth
- 6.2.3 SYSTEM AND TECHNICAL SUPPORT SERVICES
- 6.2.3.1 Need for continuous technical support to propel segment growth
- 6.2.4 TRIAL DESIGN AND CONSULTING SERVICES
- 6.2.4.1 High R&D spending and favorable government initiatives for clinical trials to fuel market growth
- 6.3 SOFTWARE
- 6.3.1 NEED FOR HIGHLY EFFICIENT AND COST-EFFECTIVE CLINICAL OPERATIONS SOFTWARE TO FAVOR MARKET GROWTH
7 CLINICAL TRIAL IMAGING MARKET, BY MODALITY
- 7.1 INTRODUCTION
- 7.2 COMPUTED TOMOGRAPHY
- 7.2.1 HIGHER CONTRAST IMAGE AND QUICKER TEST RESULTS TO AUGMENT SEGMENT GROWTH
- 7.3 MAGNETIC RESONANCE IMAGING
- 7.3.1 GREATER OBJECTIVITY, SENSITIVITY, AND REPRODUCIBILITY TO PROPEL MARKET GROWTH
- 7.4 ULTRASOUND
- 7.4.1 COST-EFFECTIVENESS AND EASE OF USE TO FUEL MARKET GROWTH
- 7.5 POSITRON EMISSION TOMOGRAPHY
- 7.5.1 ABILITY TO ASSESS PHARMACOKINETIC AND PHARMACODYNAMIC EVENTS IN HUMANS AND ANIMALS TO BOOST MARKET GROWTH
- 7.6 X-RAY
- 7.6.1 LOW SCANNING COST AND TECHNOLOGICAL ADVANCEMENTS TO FAVOR MARKET GROWTH
- 7.7 OTHER MODALITIES
8 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA
- 8.1 INTRODUCTION
- 8.2 ONCOLOGY
- 8.2.1 GROWING INCIDENCE OF CANCER AND INCREASING R&D INVESTMENTS BY PHARMA COMPANIES TO AID MARKET GROWTH
- 8.3 INFECTIOUS DISEASES
- 8.3.1 RISING DRUG DISCOVERY ACTIVITY AND GROWING DEMAND FOR THERAPEUTICS TO SPUR MARKET GROWTH
- 8.4 NEUROLOGY
- 8.4.1 HIGH RESEARCH INVESTMENTS FOR NEUROLOGIC DRUGS TO PROPEL MARKET GROWTH
- 8.5 CARDIOVASCULAR SYSTEM DISORDERS
- 8.5.1 HIGH MORTALITY RATE AND COMPLEX CLINICAL TRIAL PROCEDURES TO AUGMENT MARKET GROWTH
- 8.6 ENDOCRINOLOGY
- 8.6.1 RISING PREVALENCE OF DIABETES AND INCREASING RESEARCH FUNDING FOR METABOLIC DISORDERS TO DRIVE MARKET
- 8.7 IMMUNOLOGICAL DISORDERS
- 8.7.1 WIDE PREVALENCE OF ALLERGIES, ASTHMA, AND AUTOIMMUNE DISEASES TO SUPPORT MARKET GROWTH
- 8.8 OTHER THERAPEUTIC AREAS
9 CLINICAL TRIAL IMAGING MARKET, BY END USER
- 9.1 INTRODUCTION
- 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 9.2.1 HIGH R&D BUDGETS AND FAVORABLE GOVERNMENT INITIATIVES TO SUPPORT MARKET GROWTH
- 9.3 MEDICAL DEVICE MANUFACTURERS
- 9.3.1 HIGH SPENDING ON R&D AND CLINICAL TRIALS TO SUPPORT MARKET GROWTH
- 9.4 CONTRACT RESEARCH ORGANIZATIONS
- 9.4.1 INCREASING TREND OF OUTSOURCING AND GROWING PATIENT POPULATION IN EMERGING ECONOMIES TO AID MARKET GROWTH
- 9.5 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
- 9.5.1 RISING RESEARCH FUNDING AND INCREASING GOVERNMENT SUPPORT FOR CLINICAL TRIALS TO BOOST MARKET GROWTH
- 9.6 OTHER END USERS
10 CLINICAL TRIAL IMAGING MARKET, BY REGION
- 10.1 INTRODUCTION
- 10.2 NORTH AMERICA
- 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 10.2.2 US
- 10.2.2.1 US to dominate North American clinical trial imaging market during study period
- 10.2.3 CANADA
- 10.2.3.1 Increase in per capita healthcare spending to augment market growth
- 10.3 EUROPE
- 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 10.3.2 GERMANY
- 10.3.2.1 Strong medical technology infrastructure and increased funding for biomedical research to augment market growth
- 10.3.3 UK
- 10.3.3.1 Increased R&D investments and high per capita healthcare expenditure to augment market growth
- 10.3.4 FRANCE
- 10.3.4.1 Developed generics market and favorable government healthcare policies to support market growth
- 10.3.5 ITALY
- 10.3.5.1 Increasing number of drug approvals and rising investments in clinical trials to drive market
- 10.3.6 SPAIN
- 10.3.6.1 Increased biologics production and improved healthcare infrastructure to aid market growth
- 10.3.7 REST OF EUROPE
- 10.4 ASIA PACIFIC
- 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 10.4.2 CHINA
- 10.4.2.1 Favorable government regulations and presence of large target patient population to boost market growth
- 10.4.3 JAPAN
- 10.4.3.1 Increasing geriatric population and rising healthcare expenditure to favor market growth
- 10.4.4 INDIA
- 10.4.4.1 Increased government focus on developing advanced healthcare infrastructure to augment market growth
- 10.4.5 REST OF ASIA PACIFIC
- 10.5 LATIN AMERICA
- 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 10.5.2 BRAZIL
- 10.5.2.1 Increasing investments in biopharmaceutical research to propel market growth
- 10.5.3 MEXICO
- 10.5.3.1 Developed pharmaceutical and biotechnology industry and high demand for personalized medicines to aid market growth
- 10.5.4 REST OF LATIN AMERICA
- 10.6 MIDDLE EAST & AFRICA
- 10.6.1 INCREASED FUNDING AND COLLABORATIONS IN RESEARCH SECTOR TO DRIVE MARKET
- 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
- 10.7 GCC COUNTRIES
- 10.7.1 INCREASING RESEARCH ACTIVITIES AND GROWING BIOTECHNOLOGY INDUSTRY TO SPUR MARKET GROWTH
- 10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
11 COMPETITIVE LANDSCAPE
- 11.1 INTRODUCTION
- 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
- 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CLINICAL TRIAL IMAGING MARKET
- 11.3 REVENUE ANALYSIS, 2021-2023
- 11.4 MARKET SHARE ANALYSIS, 2023
- 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (2023)
- 11.5.1 STARS
- 11.5.2 EMERGING LEADERS
- 11.5.3 PERVASIVE PLAYERS
- 11.5.4 PARTICIPANTS
- 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
- 11.5.5.1 Company footprint
- 11.5.5.2 Service & software footprint
- 11.5.5.3 Therapeutic area footprint
- 11.5.5.4 Region footprint
- 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 11.6.1 PROGRESSIVE COMPANIES
- 11.6.2 RESPONSIVE COMPANIES
- 11.6.3 DYNAMIC COMPANIES
- 11.6.4 STARTING BLOCKS
- 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 11.7 COMPANY VALUATION AND FINANCIAL METRICS
- 11.8 COMPETITIVE SCENARIO
- 11.8.1 SERVICE AND SOLUTION LAUNCHES AND REGULATORY APPROVALS
- 11.8.2 DEALS
12 COMPANY PROFILES
- 12.1 KEY PLAYERS
- 12.1.1 ICON PLC
- 12.1.1.1 Business overview
- 12.1.1.2 Services/Solutions offered
- 12.1.1.3 Recent developments
- 12.1.1.3.1 Solution launches
- 12.1.1.3.2 Deals
- 12.1.1.4 MnM view
- 12.1.1.4.1 Key strengths
- 12.1.1.4.2 Strategic choices
- 12.1.1.4.3 Weaknesses and competitive threats
- 12.1.2 MEDPACE
- 12.1.2.1 Business overview
- 12.1.2.2 Services/Solutions offered
- 12.1.2.3 MnM view
- 12.1.2.3.1 Key strengths
- 12.1.2.3.2 Strategic choices
- 12.1.2.3.3 Weaknesses and competitive threats
- 12.1.3 CLARIO
- 12.1.3.1 Business overview
- 12.1.3.2 Services/Solutions offered
- 12.1.3.3 Recent developments
- 12.1.3.3.1 Solution launches
- 12.1.3.3.2 Deals
- 12.1.3.4 MnM view
- 12.1.3.4.1 Key strengths
- 12.1.3.4.2 Strategic choices
- 12.1.3.4.3 Weaknesses and competitive threats
- 12.1.4 IXICO PLC
- 12.1.4.1 Business overview
- 12.1.4.2 Services/Solutions offered
- 12.1.4.3 Recent developments
- 12.1.4.3.1 Deals
- 12.1.4.3.2 Other developments
- 12.1.5 RESONANCE HEALTH LTD.
- 12.1.5.1 Business overview
- 12.1.5.2 Services/Solutions offered
- 12.1.5.3 Recent developments
- 12.1.5.3.1 Service launches and regulatory approvals
- 12.1.5.3.2 Deals
- 12.1.6 RADIANT SAGE
- 12.1.6.1 Business overview
- 12.1.6.2 Services/Solutions offered
- 12.1.7 WCG CLINICAL
- 12.1.7.1 Business overview
- 12.1.7.2 Services/Solutions offered
- 12.1.7.3 Recent developments
- 12.1.8 CARDIOVASCULAR IMAGING TECHNOLOGIES
- 12.1.8.1 Business overview
- 12.1.8.2 Services/Solutions offered
- 12.2 OTHER PLAYERS
- 12.2.1 MEDICAL METRICS, INC.
- 12.2.2 PRISM CLINICAL IMAGING
- 12.2.3 BOSTON IMAGING CORE LAB
- 12.2.4 ANAGRAM 4 CLINICAL TRIALS
- 12.2.5 VOIANT
- 12.2.6 CALYX
- 12.2.7 BIOSPECTIVE INC.
- 12.2.8 PROSCAN IMAGING
- 12.2.9 MICRON, INC.
- 12.2.10 IMAGING ENDPOINTS
- 12.2.11 PERSPECTUM
- 12.2.12 PHARMTRACE
- 12.2.13 NAVITAS LIFE SCIENCES
- 12.2.14 MEDIAN TECHNOLOGIES
- 12.2.15 INVICRO, LLC
- 12.2.16 IMAGE CORE LAB
- 12.2.17 IMAGE ANALYSIS GROUP (IAG)
13 APPENDIX
- 13.1 DISCUSSION GUIDE
- 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 13.3 CUSTOMIZATION OPTIONS
- 13.4 RELATED REPORTS
- 13.5 AUTHOR DETAILS
